Actively Recruiting
Postpartum Low-Dose Aspirin and Preeclampsia
Led by Columbia University · Updated on 2026-01-22
100
Participants Needed
1
Research Sites
384 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg) or placebo to take daily for up to 3 weeks post-delivery. Exploratory objective includes healthy control postpartum patients without preeclampsia and not on LDA during pregnancy or postpartum in comparison with the primary study population affected by preeclampsia with severe features.
CONDITIONS
Official Title
Postpartum Low-Dose Aspirin and Preeclampsia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Singleton or multiple pregnancy
- Maternal age 18 years or older
- Pregnancy at 20 weeks gestation or later
- Diagnosis of severe preeclampsia before delivery
You will not qualify if you...
- Use of aspirin postpartum for other medical reasons
- Use of Lovenox, unfractionated heparin, or other anticoagulants postpartum except postoperative use in hospital
- Aspirin use within 7 days before initial postpartum blood vessel function test
- Allergy or sensitivity to aspirin or salicylates
- Allergy or sensitivity to nonsteroidal anti-inflammatory drugs unless taking low-dose aspirin during pregnancy
- Nasal polyps
- History of gastric or duodenal ulcers or gastrointestinal bleeding
- Severe liver dysfunction
- Bleeding disorders
- Breastfeeding a newborn with low platelets (NAIT)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Columbia University Irving Medical Center
New York, New York, United States, 10032
Actively Recruiting
Research Team
A
Aleha Aziz, MD, MPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here